The incidence of CHD is still increasing, which underscores the need for new preventive and therapeutic approaches to decrease CHD risk. In this respect, increasing apoA-I concentrations may be a promising approach, especially through increasing apoA-I synthesis. This review first provides insight into current knowledge on apoA-I production, clearance, and degradation, followed by a systematic review of dietary and novel pharmacological approaches to target apoA-I metabolism. For this, a systematic search was performed to identify randomized controlled intervention studies that examined effects of whole foods and (non) nutrients on apoA-I metabolism. In addition, novel pharmacological approaches were searched for, which were specifically de...
Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reduc-tase inhibitor (pravastatin sodium) can selectively...
Obesity is a pathologic condition generated by an energy imbalance, that is, excess caloric consumpt...
Background—Abundant data indicate that overexpression of apolipoprotein A-I (apoA-I) in mice inhibit...
The incidence of CHD is still increasing, which underscores the need for new preventive and therapeu...
The incidence of CHD is still increasing, which underscores the need for new preventive and therapeu...
Dyslipidemia leading to coronary heart diseases (CHD) enables venues to prevent or treat CHD by othe...
Abstract: Cholesterol is transported around the body in the form of lipoprotein (lipid/protein) comp...
Hypercholesterolemia is a clinical situation characterized by the elevated serum cholesterol and ass...
Apolipoprotein A-I (ApoA-I) is the major protein of high density lipoprotein (HDL) particles and has...
Apolipoprotein A-I (apoA-I), the main protein constituent of HDL, has a central role in the reverse ...
Although increasing apolipoprotein A-I (apoA-I) might lower the cardiovascular disease risk, knowled...
The relationship between levels of high-density lipoprotein cholesterol (HDL-C) and cardiovascular (...
ing including cancer, coronary heart disease, type II diabetes, hypertension and stroke. Compelling ...
Apolipoprotein A-I (apoA-I) is a 243 amino-acid cysteine deficient protein, containing 10 amphipathi...
Coronary heart disease (CHD) is the leading cause of morbidity and mortality in the developed world....
Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reduc-tase inhibitor (pravastatin sodium) can selectively...
Obesity is a pathologic condition generated by an energy imbalance, that is, excess caloric consumpt...
Background—Abundant data indicate that overexpression of apolipoprotein A-I (apoA-I) in mice inhibit...
The incidence of CHD is still increasing, which underscores the need for new preventive and therapeu...
The incidence of CHD is still increasing, which underscores the need for new preventive and therapeu...
Dyslipidemia leading to coronary heart diseases (CHD) enables venues to prevent or treat CHD by othe...
Abstract: Cholesterol is transported around the body in the form of lipoprotein (lipid/protein) comp...
Hypercholesterolemia is a clinical situation characterized by the elevated serum cholesterol and ass...
Apolipoprotein A-I (ApoA-I) is the major protein of high density lipoprotein (HDL) particles and has...
Apolipoprotein A-I (apoA-I), the main protein constituent of HDL, has a central role in the reverse ...
Although increasing apolipoprotein A-I (apoA-I) might lower the cardiovascular disease risk, knowled...
The relationship between levels of high-density lipoprotein cholesterol (HDL-C) and cardiovascular (...
ing including cancer, coronary heart disease, type II diabetes, hypertension and stroke. Compelling ...
Apolipoprotein A-I (apoA-I) is a 243 amino-acid cysteine deficient protein, containing 10 amphipathi...
Coronary heart disease (CHD) is the leading cause of morbidity and mortality in the developed world....
Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reduc-tase inhibitor (pravastatin sodium) can selectively...
Obesity is a pathologic condition generated by an energy imbalance, that is, excess caloric consumpt...
Background—Abundant data indicate that overexpression of apolipoprotein A-I (apoA-I) in mice inhibit...